A Phase 1 interventional study of BNT162b1 and Placebo in SARS-CoV-2, sponsored by BioNTech SE. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.
Sponsored by BioNTech SE · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 42nd largest by enrollment, is one of 5 that started in 2020, is the only one in phase 1, and was the 3rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 29th largest by enrollment, is one of 10 that started in 2020, is one of 4 in phase 1, and was the 5th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.
The participants were screened for 2 weeks (Day -14 to Day 0) before randomization, and received 1 dose of SARS-CoV-2 vaccine (BNT162b1) or placebo intramuscularly (IM) on Day 1 and Day 22, respectively. After randomization, the study for each participant lasted for approximately 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For adult group (age ≥18 and ≤55)
For the elderly group (age ≥65 and ≤85)
Exclusion Criteria:
For adult group (age ≥18 and ≤55)
For the elderly group (age ≥65 and ≤85)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BNT162b1
Biological: BNT162b1
Other: Placebo
Biological: BNT162b1
Biological: BNT162b1
Other: Placebo
Intramuscular injection
Intramuscular injection
Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.
Solicited local AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by United States (US) Food and Drug Administration (FDA) criteria along with the 14-day period AE assessment as graded by National Medical Products Administration (NMPA) criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. All the solicited local AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo).
Time frame: Up to 14 days following each dose administration
Number of Participants With Solicited Systemic AEs (e.g., e.g., Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.
Solicited systemic AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by US FDA criteria along with the 14-day period AE assessment as graded by NMPA criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. Except for 1 event (myalgia) occurred in 10 µg group and 1 event (diarrhea) occurred in placebo group, all the solicited systemic AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo). All the solicited systemic AEs occurred within 14 days after vaccination were related to investigational vaccine (or placebo), except for 1 event (myalgia) occurred in placebo group and 2 events (both diarrhea; 1 event occurred in 30 µg group, 1 event occurred in placebo group).
Time frame: Up to 14 days following each dose administration
Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.
AEs occurred during the 21-day period after dose 1 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.
Time frame: 21-day period after dose 1 vaccination
Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.
AEs occurred during the 28-day period after dose 2 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.
Time frame: 28-day period after dose 2 vaccination
The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)
Time frame: From Dose 1 up to Month 12
The Number of Participants Experiencing Related TEAEs
"Related" implies the relationship between AE and vaccine is one of "Possibly related", "Probably related" and "Definitely related".
Time frame: From Dose 1 up to Month 12
The Number of Participants Experiencing Clinically Significant (CS) Abnormal Markers of Hematology, Blood Chemistry and Urine Analysis
Results for CS results are displayed by abnormal parameter. Abnormal test results assessed not clinical significant are not presented. Participants with more than one 'CS' parameter are counted for each parameter separately and therefore included multiple times.
Time frame: Hour 24 and Day 7 after dose 1 and Day 7 after dose 2
Geometric Mean Titer (GMT) of Anti-S1 IgG Antibody
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.
Time frame: Up to 12 months following first dose
GMT of Anti-receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.
Time frame: Up to 12 months following first dose
GMT of SARS-CoV-2 Neutralizing Antibody (Including True Virus-based SARS-CoV-2 Neutralizing Test)
At Day 7, Day 21 after first dose, at Day 7, Day 21 after second dose, and at Month 3, 6, and 12 after first dose.
Time frame: Up to 12 months following first dose
Fold Increase in Antibody Anti-S1 IgG Antibody Titers, as Compared to Baseline
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.
Time frame: Up to 12 months following the first dose
Fold Increase in Antibody Anti-RBD IgG Antibody Titers, as Compared to Baseline
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.
Time frame: Up to 12 months following first dose
Fold Increase in SARS-CoV-2 Neutralizing Antibody Titers (Virus Neutralizing Test), as Compared to Baseline.
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.
Time frame: Up to 12 months following first dose
Seroconversion Rates (SCR) Defined as a Minimum of 4-fold Increase of Antibody Titers, as Compared to Baseline
At Day 7, Day 21 after dose 1, and at Day 7, Day 21 after dose 2.
Time frame: Up to 21 days after dose 2
A total of 144 subjects were randomized in this phase I clinical trial, including 72 adult subjects aged 18-55 years old (including boundary value) and 72 elderly subjects aged 65-85 years old (including boundary value). The subjects received either BNT162b1 10 µg (low dose), BNT162b1 30 µg (high dose), or placebo on Day 1 and Day 22, respectively.
| Milestone | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Started | 24 | 24 | 24 | 24 | 24 | 24 |
| Completed | 24 | 24 | 24 | 23 | 23 | 24 |
| Not completed | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 0 |
| Milestone | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Started | 24 | 24 | 24 | 23 | 23 | 24 |
| Completed | 23 | 24 | 23 | 22 | 22 | 23 |
| Not completed | 1 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Inoculated with other covid-19 vaccine | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 |
Solicited local AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by United States (US) Food and Drug Administration (FDA) criteria along with the 14-day period AE assessment as graded by National Medical Products Administration (NMPA) criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. All the solicited local AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo).
| Participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Within 7 days after dose 1: Number of participants with solicited local AEs | 19 | 24 | 1 | 13 | 19 | 0 |
| Within 7 days after dose 2: Number of participants with solicited local AEs | 17 | 20 | 1 | 15 | 15 | 0 |
| Within 7 days after dose 1: Number of participants with solicited local AEs grade 3 (FDA criteria) | 0 | 0 | 0 | 0 | 0 | 0 |
| Within 7 days after dose 2: Number of participants with solicited local AEs grade 3 (FDA criteria) | 0 | 0 | 0 | 0 | 0 | 0 |
| Within 14 days after dose 1: Number of participants with solicited local AEs grade 3 (NMPA criteria) | 0 | 0 | 0 | 0 | 0 | 0 |
| Within 14 days after dose 2: Number of participants with solicited local AEs grade 3 (NMPA criteria) | 0 | 0 | 0 | 0 | 0 | 0 |
Solicited systemic AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by US FDA criteria along with the 14-day period AE assessment as graded by NMPA criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. Except for 1 event (myalgia) occurred in 10 µg group and 1 event (diarrhea) occurred in placebo group, all the solicited systemic AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo). All the solicited systemic AEs occurred within 14 days after vaccination were related to investigational vaccine (or placebo), except for 1 event (myalgia) occurred in placebo group and 2 events (both diarrhea; 1 event occurred in 30 µg group, 1 event occurred in placebo group).
| Participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Within 7 d (days) after dose 1: Number of participants with solicited systemic AEs | 9 | 16 | 3 | 3 | 15 | 2 |
| Within 7 d after dose 2: Number of participants with solicited systemic AEs | 15 | 21 | 3 | 7 | 17 | 1 |
| Within 14 d after dose 1: Number of participants with solicited systemic AEs | 10 | 16 | 3 | 3 | 15 | 2 |
| Within 14 d after dose 2: Number of participants with solicited systemic AEs | 15 | 21 | 3 | 7 | 17 | 2 |
| Within 7 d after dose 1: Number of participants with related solicited systemic AEs grade 3 (FDA) | 0 | 1 | 0 | 0 | 2 | 0 |
| Within 7 d after dose 2: Number of participants with related solicited systemic AEs grade 3 (FDA) | 1 | 3 | 0 | 0 | 0 | 0 |
| Within 14 d after dose 1: Number of participants with related solicited systemic AEs grade 3 (NMPA) | 0 | 5 | 0 | 0 | 2 | 0 |
| Within 14 d after dose 2: Number of participants with related solicited systemic AEs grade 3 (NMPA) | 3 | 6 | 0 | 0 | 0 | 0 |
AEs occurred during the 21-day period after dose 1 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.
| participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo. | 7 | 7 | 1 | 2 | 5 | 2 |
AEs occurred during the 28-day period after dose 2 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.
| participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo. | 5 | 8 | 0 | 2 | 7 | 0 |
| participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs) | 0 | 1 | 1 | 1 | 0 | 0 |
"Related" implies the relationship between AE and vaccine is one of "Possibly related", "Probably related" and "Definitely related".
| participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Number of Participants with related TEAEs after dose 1 | 22 | 24 | 4 | 16 | 21 | 4 |
| Number of Participants with related TEAEs after dose 2 | 20 | 22 | 4 | 18 | 21 | 0 |
Results for CS results are displayed by abnormal parameter. Abnormal test results assessed not clinical significant are not presented. Participants with more than one 'CS' parameter are counted for each parameter separately and therefore included multiple times.
| Participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| CS abnormal blood chemistry parameter - increased total bilirubin - 24 hours after dose 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| CS abnormal blood chemistry parameter - increased total bilirubin - Day 7 after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal blood chemistry parameter - increased total bilirubin - Day 7 after dose 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - elevated leucocyte (microscopic) - 24 hours after dose 1 | 1 | 0 | 1 | 0 | 0 | 1 |
| CS abnormal urine routine test results - elevated leucocyte (microscopic) - Day 7 after dose 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| CS abnormal urine routine test results - elevated leucocyte (microscopic) - Day 7 after dose 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - bacteria (microscopic) - 24 hours after dose 1 | 1 | 0 | 1 | 0 | 0 | 1 |
| CS abnormal urine routine test results - bacteria (microscopic) - Day 7 after dose 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| CS abnormal urine routine test results - bacteria (microscopic) - Day 7 after dose 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| CS abnormal urine routine test results - red blood cells (microscopic) - 24 hours after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - red blood cells (microscopic) - Day 7 after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - red blood cells (microscopic) - Day 7 after dose 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| CS abnormal urine routine test results - glucose - 24 hours after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - glucose - Day 7 after dose 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| CS abnormal urine routine test results - glucose - Day 7 after dose 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - ketone - 24 hours after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - ketone - Day 7 after dose 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| CS abnormal urine routine test results - ketone - Day 7 after dose 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - blood - 24 hours after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - blood - Day 7 after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal urine routine test results - blood - Day 7 after dose 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| CS abnormal hematology parameter - hemoglobin - 24 hours after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - hemoglobin - Day 7 after dose 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - hemoglobin - Day 7 after dose 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - hematocrit - 24 hours after dose 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - hematocrit - Day 7 after dose 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - hematocrit - Day 7 after dose 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - lymphocyte - 24 hours after dose 1 | 3 | 5 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - lymphocyte - Day 7 after dose 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| CS abnormal hematology parameter - lymphocyte - Day 7 after dose 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| CS abnormal hematology parameter - platelet count - 24 hours after dose 1 | 0 | 2 | 0 | 1 | 2 | 0 |
| CS abnormal hematology parameter - platelet count - Day 7 after dose 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| CS abnormal hematology parameter - platelet count - Day 7 after dose 2 | 0 | 0 | 2 | 1 | 0 | 0 |
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.
| titer | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| 7 days after dose 1 | 53.320 (46.680 to 60.905) | 59.220 (41.728 to 84.046) | 52.841 (47.132 to 59.242) | — | — | — |
| 21 days after dose 1 | 4193.710 (2664.050 to 6601.681) | 4531.416 (3029.130 to 6778.757) | 52.594 (47.369 to 58.395) | 859.646 (467.549 to 1580.564) | 2872.861 (1685.729 to 4896.002) | 62.239 (47.583 to 81.410) |
| 7 days after dose 2 | 26548.853 (18381.541 to 38345.078) | 41530.498 (33984.171 to 50752.518) | 52.578 (47.384 to 58.341) | 5271.560 (2484.575 to 11184.748) | 23447.197 (15268.301 to 36007.348) | 62.658 (47.633 to 82.423) |
| 21 days after dose 2 | 46810.469 (41673.251 to 52580.970) | 49773.381 (46947.113 to 52769.794) | 50.000 (50.000 to 50.000) | 40942.862 (33177.420 to 50525.869) | 44159.581 (37139.275 to 52506.910) | 61.008 (45.725 to 81.399) |
| Month 3 after dose 1 | 27143.015 (21023.440 to 35043.897) | 31584.450 (26378.938 to 37817.196) | 50.000 (50.000 to 50.000) | — | — | — |
| Month 6 after dose 1 | 4169.448 (2978.898 to 5835.815) | 5693.082 (4412.125 to 7345.934) | 55.088 (47.853 to 63.417) | 2223.699 (1565.907 to 3157.811) | 4970.376 (3625.506 to 6814.121) | 60.931 (45.837 to 80.995) |
| Month 12 after dose 1 | 2002.152 (1389.905 to 2884.090) | 2792.605 (2118.269 to 3681.610) | 50.000 (50.000 to 50.000) | 1104.860 (698.932 to 1746.542) | 2847.010 (1887.353 to 4294.621) | 53.105 (46.867 to 60.174) |
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.
| titer | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| 7 days after dose 1 | 50.000 (50.000 to 50.000) | 52.903 (47.074 to 59.453) | 56.644 (48.999 to 65.482) | — | — | — |
| 21 days after dose 1 | 13095.167 (8395.009 to 20426.827) | 13046.378 (8950.882 to 19015.777) | 56.699 (49.052 to 65.537) | 3040.808 (1569.768 to 5890.369) | 10370.854 (5955.358 to 18060.142) | 74.476 (55.679 to 99.618) |
| 7 days after dose 2 | 38314.550 (30173.509 to 48652.107) | 47324.691 (43213.653 to 51826.824) | 57.377 (49.028 to 67.146) | 10748.566 (5512.317 to 20958.821) | 38256.083 (30078.753 to 48656.534) | 75.817 (55.962 to 102.715) |
| 21 days after dose 2 | 49710.291 (46764.743 to 52841.369) | 51200.000 (51200.000 to 51200.000) | 60.605 (48.454 to 75.804) | 46980.825 (42021.855 to 52525.000) | 50977.162 (50528.938 to 51429.363) | 65.756 (53.237 to 81.218) |
| Month 3 after dose 1 | 40236.195 (32999.573 to 49059.768) | 43050.715 (38767.819 to 47806.766) | 60.439 (49.911 to 73.188) | — | — | — |
| Month 6 after dose 1 | 8249.604 (6186.091 to 11001.449) | 9608.488 (7410.049 to 12459.167) | 61.768 (50.272 to 75.894) | 4114.353 (2716.614 to 6231.250) | 7187.827 (5138.636 to 10054.194) | 54.780 (48.060 to 62.439) |
| Month 12 after dose 1 | 2324.072 (1677.862 to 3219.163) | 2804.882 (2191.409 to 3590.094) | 56.083 (47.501 to 66.216) | 1536.143 (921.738 to 2560.094) | 2768.366 (1880.754 to 4074.881) | 63.175 (50.876 to 78.447) |
At Day 7, Day 21 after first dose, at Day 7, Day 21 after second dose, and at Month 3, 6, and 12 after first dose.
| titer | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| 7 days after dose 1 | 5.000 (5.000 to 5.000) | 5.000 (5.000 to 5.000) | 5.000 (5.000 to 5.000) | — | — | — |
| 21 days after dose 1 | 18.877 (10.586 to 33.664) | 14.557 (9.712 to 21.817) | 5.000 (5.000 to 5.000) | 6.965 (5.037 to 9.633) | 10.946 (7.213 to 16.612) | 5.000 (5.000 to 5.000) |
| 7 days after dose 2 | 56.569 (31.503 to 101.579) | 119.865 (81.547 to 176.187) | 5.000 (5.000 to 5.000) | 14.357 (8.689 to 23.721) | 49.394 (26.334 to 92.647) | 5.000 (5.000 to 5.000) |
| 21 days after dose 2 | 232.905 (151.299 to 358.525) | 253.984 (184.601 to 349.445) | 5.000 (5.000 to 5.000) | 80.000 (49.173 to 130.153) | 160.000 (96.736 to 264.637) | 5.000 (5.000 to 5.000) |
| Month 3 after dose 1 | 54.958 (38.115 to 79.245) | 87.241 (64.445 to 118.099) | 5.000 (5.000 to 5.000) | — | — | — |
| Month 6 after dose 1 | 16.339 (11.274 to 23.679) | 27.479 (20.383 to 37.046) | 5.000 (5.000 to 5.000) | 10.000 (7.219 to 13.852) | 20.612 (13.303 to 31.937) | 5.000 (5.000 to 5.000) |
| Month 12 after dose 1 | 7.858 (6.027 to 10.244) | 11.892 (8.903 to 15.885) | 5.000 (5.000 to 5.000) | 6.040 (4.976 to 7.333) | 12.081 (8.154 to 17.899) | 5.000 (5.000 to 5.000) |
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.
| fold rise | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| 7 days after dose 1 | 0.960 (0.899 to 1.025) | 0.998 (0.993 to 1.002) | 0.992 (0.976 to 1.008) | — | — | — |
| 21 days after dose 1 | 75.535 (45.607 to 125.103) | 76.351 (48.641 to 119.845) | 0.988 (0.962 to 1.013) | 16.501 (8.998 to 30.260) | 52.377 (30.969 to 88.586) | 0.997 (0.991 to 1.002) |
| 7 days after dose 2 | 478.186 (316.204 to 723.147) | 699.755 (473.456 to 1034.219) | 0.987 (0.961 to 1.014) | 101.189 (47.897 to 213.776) | 427.484 (281.104 to 650.090) | 1.003 (0.998 to 1.008) |
| 21 days after dose 2 | 843.129 (696.113 to 1021.194) | 838.640 (586.916 to 1198.328) | 0.939 (0.824 to 1.070) | 785.911 (631.437 to 978.175) | 805.108 (655.534 to 988.810) | 0.977 (0.896 to 1.065) |
| Month 3 after dose 1 | 488.888 (359.289 to 665.234) | 532.172 (371.322 to 762.699) | 0.939 (0.824 to 1.070) | — | — | — |
| Month 6 after dose 1 | 75.098 (50.105 to 112.558) | 95.924 (66.863 to 137.614) | 1.028 (0.939 to 1.126) | 42.685 (29.500 to 61.762) | 90.619 (64.457 to 127.399) | 0.966 (0.886 to 1.054) |
| Month 12 after dose 1 | 35.898 (23.326 to 55.246) | 47.053 (33.587 to 65.918) | 0.936 (0.817 to 1.073) | 21.169 (13.164 to 34.039) | 51.688 (34.959 to 76.423) | 0.842 (0.664 to 1.069) |
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.
| fold rise | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| 7 days after dose 1 | 1.000 (1.000 to 1.000) | 1.001 (0.998 to 1.005) | 0.985 (0.968 to 1.003) | — | — | — |
| 21 days after dose 1 | 261.903 (167.900 to 408.537) | 246.976 (172.957 to 352.672) | 0.986 (0.964 to 1.009) | 51.597 (28.409 to 93.710) | 150.858 (74.500 to 305.479) | 1.001 (0.985 to 1.018) |
| 7 days after dose 2 | 766.291 (603.470 to 973.042) | 895.886 (778.927 to 1030.407) | 0.998 (0.973 to 1.023) | 182.382 (96.770 to 343.735) | 556.487 (351.897 to 880.024) | 1.020 (0.981 to 1.059) |
| 21 days after dose 2 | 994.206 (935.295 to 1056.827) | 969.249 (865.101 to 1085.934) | 1.054 (0.990 to 1.122) | 797.173 (645.312 to 984.773) | 741.532 (498.207 to 1103.699) | 0.884 (0.753 to 1.038) |
| Month 3 after dose 1 | 804.724 (659.991 to 981.195) | 814.977 (706.611 to 939.963) | 1.051 (0.970 to 1.140) | — | — | — |
| Month 6 after dose 1 | 164.992 (123.722 to 220.029) | 181.895 (145.883 to 226.796) | 1.061 (0.889 to 1.267) | 69.813 (47.788 to 101.988) | 104.557 (65.750 to 166.268) | 0.764 (0.615 to 0.950) |
| Month 12 after dose 1 | 46.481 (33.557 to 64.383) | 53.098 (42.807 to 65.863) | 0.970 (0.893 to 1.053) | 25.871 (16.436 to 40.724) | 41.548 (25.869 to 66.729) | 0.835 (0.690 to 1.010) |
At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.
| fold rise | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| 7 days after dose 1 | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | — | — | — |
| 21 days after dose 1 | 3.775 (2.117 to 6.733) | 2.911 (1.942 to 4.363) | 1.000 (1.000 to 1.000) | 1.393 (1.007 to 1.927) | 2.189 (1.443 to 3.322) | 1.000 (1.000 to 1.000) |
| 7 days after dose 2 | 11.314 (6.301 to 20.316) | 23.973 (16.309 to 35.237) | 1.000 (1.000 to 1.000) | 2.871 (1.738 to 4.744) | 9.879 (5.267 to 18.529) | 1.000 (1.000 to 1.000) |
| 21 days after dose 2 | 46.581 (30.260 to 71.705) | 50.797 (36.920 to 69.889) | 1.000 (1.000 to 1.000) | 16.000 (9.835 to 26.031) | 32.000 (19.347 to 52.927) | 1.000 (1.000 to 1.000) |
| Month 3 after dose 1 | 10.992 (7.623 to 15.849) | 17.448 (12.889 to 23.620) | 1.000 (1.000 to 1.000) | — | — | — |
| Month 6 after dose 1 | 3.268 (2.255 to 4.736) | 5.496 (4.077 to 7.409) | 1.000 (1.000 to 1.000) | 2.000 (1.444 to 2.770) | 4.122 (2.661 to 6.387) | 1.000 (1.000 to 1.000) |
| Month 12 after dose 1 | 1.572 (1.205 to 2.049) | 2.378 (1.781 to 3.177) | 1.000 (1.000 to 1.000) | 1.208 (0.995 to 1.467) | 2.416 (1.631 to 3.580) | 1.000 (1.000 to 1.000) |
At Day 7, Day 21 after dose 1, and at Day 7, Day 21 after dose 2.
| Participants | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| SCR of SARS-CoV-2 neutralizing antibody - 7 days after dose 1 | 0 | 0 | 0 | — | — | — |
| SCR of SARS-CoV-2 neutralizing antibody - 21 days after dose 1 | 12 | 11 | 0 | 3 | 8 | 0 |
| SCR of SARS-CoV-2 neutralizing antibody - 7 days after dose 2 | 18 | 23 | 0 | 11 | 18 | 0 |
| SCR of SARS-CoV-2 neutralizing antibody - 21 days after dose 2 | 24 | 24 | 0 | 21 | 22 | 0 |
| SCR of anti-S1 IgG antibody - 7 days after dose 1 | 0 | 0 | 0 | — | — | — |
| SCR of anti-S1 IgG antibody - 21 days after dose 1 | 24 | 24 | 0 | 21 | 22 | 0 |
| SCR of anti-S1 IgG antibody - 7 days after dose 2 | 24 | 24 | 0 | 22 | 23 | 0 |
| SCR of anti-S1 IgG antibody - 21 days after dose 2 | 24 | 24 | 0 | 23 | 23 | 0 |
| SCR of anti-RBD IgG antibody - 7 days after dose 1 | 0 | 0 | 0 | — | — | — |
| SCR of anti-RBD IgG antibody - 21 days after dose 1 | 24 | 24 | 0 | 22 | 22 | 0 |
| SCR of anti-RBD IgG antibody - 7 days after dose 2 | 24 | 24 | 0 | 23 | 23 | 0 |
| SCR of anti-RBD IgG antibody - 21 days after dose 2 | 24 | 24 | 0 | 23 | 23 | 0 |
Collected over From Day 1 (Dose 1) up to last visit (approximately 12 months after first dose). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low-dose 10 µg, 18-55 Years of Age | 0/24 (0%) | 0/24 (0%) | 22/24 (91.7%) |
| High-dose 30 µg, 18-55 Years of Age | 0/24 (0%) | 1/24 (4.2%) | 24/24 (100%) |
| Placebo, 18-55 Years of Age | 0/24 (0%) | 1/24 (4.2%) | 7/24 (29.2%) |
| Low-dose 10 µg, 65-85 Years of Age | 0/24 (0%) | 1/24 (4.2%) | 22/24 (91.7%) |
| High-dose 30 µg, 65-85 Years of Age | 0/24 (0%) | 0/24 (0%) | 24/24 (100%) |
| Placebo, 65-85 Years of Age | 0/24 (0%) | 0/24 (0%) | 9/24 (37.5%) |
| Event | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| HyperthyroidismEndocrine disorders | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/24 |
| Thyroid massEndocrine disorders | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/24 |
| Thyroglossal cystCongenital, familial and genetic disorders | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 |
| Joint dislocationInjury, poisoning and procedural complications | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 |
| Humerus fractureInjury, poisoning and procedural complications | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 |
| Event | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age |
|---|---|---|---|---|---|---|
| Vaccination site painGeneral disorders | 21/24 | 23/24 | 2/24 | 16/24 | 21/24 | 0/24 |
| PyrexiaGeneral disorders | 14/24 | 21/24 | 1/24 | 7/24 | 19/24 | 1/24 |
| HeadacheNervous system disorders | 11/24 | 19/24 | 3/24 | 1/24 | 2/24 | 0/24 |
| FatigueGeneral disorders | 13/24 | 16/24 | 0/24 | 3/24 | 8/24 | 0/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/24 | 10/24 | 1/24 | 0/24 | 1/24 | 1/24 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/24 | 10/24 | 0/24 | 0/24 | 1/24 | 1/24 |
| MalaiseGeneral disorders | 8/24 | 9/24 | 0/24 | 2/24 | 4/24 | 1/24 |
| Vaccination site erythemaGeneral disorders | 6/24 | 8/24 | 0/24 | 3/24 | 4/24 | 0/24 |
| Vaccination site swellingGeneral disorders | 5/24 | 7/24 | 0/24 | 0/24 | 5/24 | 0/24 |
| ChillsGeneral disorders | 4/24 | 7/24 | 0/24 | 1/24 | 4/24 | 0/24 |
| Age, Categorical(Participants) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 24 | 24 | 0 | 0 | 0 | 72 |
| >=65 years | 0 | 0 | 0 | 24 | 24 | 24 | 72 |
| Age, Continuous(years) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| Group, 18-55 years of age | 38 ± 9.6 | 40 ± 9.0 | 42 ± 8.7 | — | — | — | 40 ± 9.2 |
| Group, 65-85 years of age | — | — | — | 71 ± 5.0 | 69 ± 3.0 | 71 ± 4.4 | 70 ± 4.2 |
| Sex: Female, Male(Participants) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| Female | 12 | 12 | 12 | 12 | 12 | 12 | 72 |
| Male | 12 | 12 | 12 | 12 | 12 | 12 | 72 |
| Race/Ethnicity, Customized(Participants) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| Asian | 24 | 24 | 24 | 24 | 24 | 24 | 144 |
| Region of Enrollment(participants) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| China | 24 | 24 | 24 | 24 | 24 | 24 | 144 |
| Weight(kg) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| Group 18-55 years of age | 69.5 ± 12.05 | 62.8 ± 10.75 | 65.7 ± 13.26 | — | — | — | 66.0 ± 12.21 |
| Group 65-85 years of age | — | — | — | 61.8 ± 9.83 | 63.8 ± 8.81 | 59.0 ± 8.36 | 61.5 ± 9.11 |
| Body mass index (BMI)(kg/m^2) | Low-dose 10 µg, 18-55 Years of Age | High-dose 30 µg, 18-55 Years of Age | Placebo, 18-55 Years of Age | Low-dose 10 µg, 65-85 Years of Age | High-dose 30 µg, 65-85 Years of Age | Placebo, 65-85 Years of Age | Total |
|---|---|---|---|---|---|---|---|
| Group 18-55 years of age | 24.7 ± 3.18 | 23.0 ± 2.71 | 24.3 ± 3.43 | — | — | — | 24.0 ± 3.16 |
| Group 65-85 years of age | — | — | — | 23.9 ± 2.95 | 24.8 ± 2.85 | 23.5 ± 2.45 | 24.1 ± 2.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Sep 2020, 2 months.
Results were first posted in Sep 2023, 2 years 11 months after primary completion.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 2 months is below that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine